Navamedic ASA: Last day of the subscription period in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITEDSTATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THEPEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THEDISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIESDESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THISANNOUNCEMENT.

Oslo, 6 October 2025: Reference is made to the previous stock exchangeannouncements published by Navamedic ASA (the "Company") regarding the partlyunderwritten rights issue of up to 6,046,511 new shares in the Company (the"Offer Shares"), at a subscription price of NOK 21.50 per Offer Share (the"Rights Issue").

The subscription period for the Rights Issue (the "Subscription Period") willexpire today, on 6 October 2025 at 16:30 hours (CEST).

Over-subscription (i.e. subscription for more Offer Shares than the number ofsubscription rights held by the subscriber entitles the subscriber to beallocated), and subscription without subscription rights, is permitted, butwithno guaranteed allocation.

Correctly completed subscription forms must be received by one of the managersof the Rights Issue, DNB Carnegie, a part of DNB Bank ASA or Nordea CorporateFinance, a part of Nordea Bank Abp, filial i Norge, or in the case of onlinesubscriptions through the CSD online subscription system be registered, by theexpiry of the Subscription Period.

Subscription rights that are not used to subscribe for Offer Shares before theexpiry of the Subscription Period will have no value and will lapse withoutcompensation to the holder.

For more information, and the complete terms and conditions of the RightsIssue,please refer to the prospectus prepared by the Company in connection with theRights Issue (the "Prospectus"). Subject to applicable local securities laws,the Prospectus, including the subscription form for the Rights Issue, is madeavailable at the Company's website www.navamedic.com(http://www.navamedic.com),as well as at www.dnb.no/emisjoner (http://www.dnb.no/emisjoner) andwww.nordea.com/en/issuances (http://www.nordea.com/en/issuances).

For more information, please contact:

Kathrine Elisabeth Gamborg Andreassen, CEO, Navamedic ASA

Tel: +47 951 78 880

Email: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic ASA

Tel: +47 917 62 842

Email: lars.hjarrand@navamedic.com

This information is subject to the disclosure requirements pursuant to Section5-12 of the Norwegian Securities Trading Act.

About Navamedic ASA

Navamedic ASA is a full-service provider of high-quality healthcare productstohospitals and pharmacies. Navamedic meets the specific medical needs ofpatientsand consumers by leveraging its highly scalable market access platform,leadingcategory competence and local knowledge. Navamedic is present in all theNordiccountries, the Baltics and Benelux, with sales representation in Greece.Navamedic is headquartered in Oslo, Norway, and listed on the Oslo StockExchange (ticker: NAVA). For more information, please visit www.navamedic.com.

- IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or asolicitation of an offer to purchase securities of the Company in the UnitedStates or any other jurisdiction. Copies of this document may not be sent tojurisdictions, or distributed in or sent from jurisdictions, in which this isbarred or prohibited by law. The securities of the Company may not be offeredorsold in the United States absent registration or an exemption fromregistrationunder the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act").The securities of the Company have not been, and will not be, registered underthe U.S. Securities Act. Any sale in the United States of the securitiesmentioned in this communication will be made solely to "qualifiedinstitutionalbuyers" as defined in Rule 144A under the U.S. Securities Act. No publicoffering of the securities will be made in the United States.

Any offering and listing of the securities referred to in this announcementhavebeen made by means of the Prospectus. This announcement is an advertisementandis not a prospectus for the purposes of Regulation (EU) 2017/1129 of theEuropean Parliament and of the Council of 14 June 2017 on prospectuses to bepublished when securities are offered to the public or admitted to trading onaregulated market, and repealing Directive 2003/71/EC (as amended) asimplementedin any EEA Member State (the "Prospectus Regulation"). The approval of theProspectus by the Financial Supervisory Authority of Norway (Nw.Finanstilsynet)should not be understood as an endorsement of the securities referred to inthisannouncement. Investors should not subscribe for any securities referred to inthis announcement except on the basis of information contained in theProspectus, to fully understand the potential risks and rewards associatedwiththe decision to invest in the securities. Copies of the Prospectus areavailablefrom the Company's registered office and, subject to certain exceptions, onthewebsite of the Managers.

In any EEA Member State other than Norway, this communication is onlyaddressedto and is only directed at qualified investors in that Member State within themeaning of the Prospectus Regulation, i.e., only to investors who can receivethe offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is onlydirected at Qualified Investors who (i) are investment professionals fallingwithin Article 19(5) of the Financial Services and Markets Act 2000 (FinancialPromotion) Order 2005 (as amended) (the "Order") or (ii) are persons fallingwithin Article 49(2)(a) to (d) of the Order (high net worth companies,unincorporated associations, etc.) (all such persons together being referredtoas "Relevant Persons"). These materials are directed only at Relevant Personsand must not be acted on or relied on by persons who are not Relevant Persons.Any investment or investment activity to which this announcement relates isavailable only to Relevant Persons and will be engaged in only with RelevantPersons. Persons distributing this communication must satisfy themselves thatitis lawful to do so.

This document is not for publication or distribution in, directly orindirectly,the United States, Canada, Australia, the Hong Kong Special AdministrativeRegion of the People's Republic of China or Japan or any other jurisdiction inwhich such release, publication or distribution would be unlawful, and it doesnot constitute an offer or invitation to subscribe for or purchase anysecurities in such countries or in any other jurisdiction. In particular, thedocument and the information contained herein should not be distributed orotherwise transmitted into the United States or to publications with a generalcirculation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issueandno one else and will not be responsible to anyone other than the Company forproviding the protections afforded to their respective clients or forprovidingadvice in relation to the Rights Issue or any transaction or arrangementreferred to in this announcement.

Matters discussed in this announcement may constitute forward-lookingstatements. Forward-looking statements are statements that are not historicalfacts and may be identified by words such as "anticipate", "believe","continue", "estimate", "expect", "intends", "may", "should", "will" andsimilarexpressions. The forward-looking statements in this release are based uponvarious assumptions, many of which are based, in turn, upon furtherassumptions.Although the Company believes that these assumptions were reasonable whenmade,these assumptions are inherently subject to significant known and unknownrisks,uncertainties, contingencies and other important factors which are difficultorimpossible to predict and are beyond its control. Such risks, uncertainties,contingencies and other important factors could cause actual events to differmaterially from the expectations expressed or implied in this release by suchforward-looking statements. The information, opinions and forward-lookingstatements contained in this announcement speak only as at its date and aresubject to change without notice. This announcement is made by and is theresponsibility of, the Company. Neither the Managers nor any of theiraffiliatesmakes any representation as to the accuracy or completeness of thisannouncementand none of them accepts any responsibility for the contents of thisannouncement or any matters referred to herein.

This announcement is for information purposes only and is not to be relieduponin substitution for the exercise of independent judgment. It is not intendedasinvestment advice and under no circumstances is it to be used or considered asan offer to sell, or a solicitation of an offer to buy any securities or arecommendation to buy or sell any securities of the Company. No reliance maybeplaced for any purpose on the information contained in this announcement oritsaccuracy, fairness or completeness. Neither the Managers nor any of theirrespective affiliates accepts any liability arising from the use of thisannouncement.

https://newsweb.oslobors.no/message/656665